1. Home
  2. SPT vs CCCC Comparison

SPT vs CCCC Comparison

Compare SPT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPT

Sprout Social Inc

HOLD

Current Price

$8.24

Market Cap

485.7M

Sector

Technology

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$4.06

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPT
CCCC
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.7M
404.7M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
SPT
CCCC
Price
$8.24
$4.06
Analyst Decision
Buy
Strong Buy
Analyst Count
8
6
Target Price
$11.75
$12.20
AVG Volume (30 Days)
1.4M
3.9M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
32.11
16.45
EPS
N/A
N/A
Revenue
$457,547,000.00
$35,947,000.00
Revenue This Year
$8.86
N/A
Revenue Next Year
$8.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.72
1.02
52 Week Low
$4.92
$1.69
52 Week High
$19.51
$5.17

Technical Indicators

Market Signals
Indicator
SPT
CCCC
Relative Strength Index (RSI) 63.82 49.47
Support Level $5.97 $2.10
Resistance Level $8.31 $4.60
Average True Range (ATR) 0.46 0.41
MACD 0.10 -0.05
Stochastic Oscillator 83.21 22.84

Price Performance

Historical Comparison
SPT
CCCC

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: